| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Department of Immunology and Center for Rheumatic Diseases, University of Glasgow, Glasgow, United Kingdom; and
Department of Immunology, University of Strathclyde, Glasgow, United Kingdom
Understanding modulation of the host immune system by pathogens offers rich therapeutic potential. Parasitic filarial nematodes are often tolerated in human hosts for decades with little evidence of pathology and this appears to reflect parasite-induced suppression of host proinflammatory immune responses. Consistent with this, we have previously described a filarial nematode-derived, secreted phosphorylcholine-containing glycoprotein, ES-62, with immunomodulatory activities that are broadly anti-inflammatory in nature. We sought to evaluate the therapeutic potential of ES-62 in vitro and in vivo in an autoimmune disease model, namely, collagen-induced arthritis in DBA/1 mice. ES-62 given during collagen priming significantly reduced initiation of inflammatory arthritis. Crucially, ES-62 was also found to suppress collagen-induced arthritis severity and progression when administration was delayed until after clinically evident disease onset. Ex vivo analyses revealed that in both cases, the effects were associated with inhibition of collagen-specific pro-inflammatory/Th1 cytokine (TNF-
, IL-6, and IFN-
) release. In parallel in vitro human tissue studies, ES-62 was found to significantly suppress macrophage activation via cognate interaction with activated T cells. Finally, ES-62 suppressed LPS-induced rheumatoid arthritis synovial TNF- and IL-6 production. Evolutionary pressure has promoted the generation by pathogens of diverse mechanisms enabling host immune system evasion and induction of "tolerance." ES-62 represents one such mechanism. We now provide proof of concept that parasite-derived immunomodulatory strategies offer a novel therapeutic opportunity in inflammatory arthritis.
This article has been cited by other articles:
|
|
 |
|
  F. A. C. Rocha, A. K. R. M. Leite, M. M. L. Pompeu, T. M. Cunha, W. A. Verri Jr., F. M. Soares, R. R. Castro, and F. Q. Cunha Protective Effect of an Extract from Ascaris suum in Experimental Arthritis Models Infect. Immun., June 1, 2008; 76(6): 2736 - 2745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Hubner, B. Pasche, S. Kalaydjiev, P. T. Soboslay, A. Lengeling, H. Schulz-Key, E. Mitre, and W. H. Hoffmann Microfilariae of the Filarial Nematode Litomosoides sigmodontis Exacerbate the Course of Lipopolysaccharide-Induced Sepsis in Mice Infect. Immun., April 1, 2008; 76(4): 1668 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M M Harnett, D E Kean, A Boitelle, S McGuiness, T Thalhamer, C N Steiger, C Egan, L Al-Riyami, M J Alcocer, K M Houston, et al. The phosphorycholine moiety of the filarial nematode immunomodulator ES-62 is responsible for its anti-inflammatory action in arthritis Ann Rheum Dis, April 1, 2008; 67(4): 518 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M Lovell, R. J Woods, D. J Butlin, K. J Brayley, I. T Manyonda, J. Jarvis, S. Howell, and P. J Lowry Identification of a novel mammalian post-translational modification, phosphocholine, on placental secretory polypeptides J. Mol. Endocrinol., September 1, 2007; 39(3): 189 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Marshall, A. M. Grierson, P. Garside, W. Harnett, and M. M. Harnett ES-62, an Immunomodulator Secreted by Filarial Nematodes, Suppresses Clonal Expansion and Modifies Effector Function of Heterologous Antigen-Specific T Cells In Vivo J. Immunol., November 1, 2005; 175(9): 5817 - 5826. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
